First quarter of 2012: Alphaform with clearly positive result
(firmenpresse) - Alphaform AG / Key word(s): Enterprise/
First quarter of 2012: Alphaform with clearly positive result
DGAP-Media / 09.05.2012 / 12:06
---------------------------------------------------------------------
Press release
First quarter of 2012:
Alphaform with clearly positive result
Revenue climbs 16.5% to EUR6.8 million compared to the quarter of
the previous year
Operating result of EUR0.2 million is clearly positive
Positive result expected for the complete year as well
Feldkirchen, 09 May 2012 - Alphaform AG, a specialist in additive
manufacturing and a leading company in the production of orthopaedic
implants and instruments, could increase the group revenue in the first
quarter of 2012 by 16.5% up to EUR6.8 million (first quarter of 2011:
EUR5.8 million). With EUR0.2 million, the company reached a positive result
before taxes (operating result) within a first quarter for the first time
since 2008 (compared to EUR-0.3 million in the same period of the previous
year). EBITDA (result before interest, taxes and deductions) climbed from
EUR0.0 million in the first quarter of 2011 to EUR0.5 million in the first
quarter of 2012.
The cash flow from operating activities in the Alphaform Group increased
from EUR-0.9 million in the first quarter of 2011 to EUR0.15 million in the
first quarter of 2012. The main reason for this is the operating result
which increased by EUR0.6 million up to EUR0.2 million. This fact is also
reflected on the gross margin, which improved by 6.5 percentage points to
72.4% as against the first quarter of the previous year. Alphaform earnings
per share amounted to EUR0.03 in the first three months of 2012 after
EUR-0.8 in the first quarter of 2011.
Prototyping further benefits from automotive development
In the first three months, the prototyping business area of Alphaform also
benefited from the stable high demand since March 2011. After the first
quarter of the previous year with EUR2.9 million - still characterized by
two weak order months - the prototype revenue rose by 38% to EUR4.0
million. Alphaform especially benefited from orders of the German
automotive industry, which is developing a number of new models in the
premium- and electric cars' segment. This situation is expected to stay
stable over the complete current year.
Medical Technology reaches better results
The medical technology business area reported a revenue reduction of 7%
compared to the quarter of the previous year: From EUR2.3 million in the
first quarter of 2011 to EUR2.2 million in the first three months of 2012.
This reduction was originated by post-processing of implants, which
formerly was commissioned by third parties and now has been insourced by
the customer. Accordingly, the share of this business area in the group
revenue decreased: From 45% in the first quarter of 2011 (40% over the
complete year 2011) to 35% in the first quarter of 2012. As a consequence
of productivity measures, EUR0.1 million cost savings could be reached in
the first quarter of 2012. These measures will also improve the result in
the current year. Further cost savings effects are expected from the
program. As order situation and customer relations are stable, Alphaform is
counting on a steadily development of the medical technology area, whose
main focus is to improve the results within this year.
The development in the Alphaform subsidiaries in the UK and Scandinavia was
positive as well: revenues rose by 30% and 35% compared to the quarter of
the previous year. As in previous year, the Alphaform Claho subsidiary has
been operating at good capacity and increased its revenue by 2% to EUR1.1
million.
Forecast for financial year 2012 is confirmed
Alphaform forecasts stable revenues at the level of the previous year for
the rest of the financial year 2012. The prototyping business is expected
to continue benefiting from the intensive development activity in the
automotive sector. A steady market development is expected in the medical
implants and instruments area, if revenues and customer base remain
unchanged. Positive impact is expected from the enhancement measure program
in medical technology and from a better product mix in prototyping area.
For the complete year 2012, Alphaform AG forecasts slightly higher revenue
compared to the previous year and as well a positive consolidated net
profit, if the economic situation remains firm.
Key figures of the Alphaform Group
EURm 1st quarterAbout Alphaform
2012 2011 Change
Revenues 6.754 5.795 16.5 %
EBITDA 0.546 0.002 27,200.0%
EBIT 0.219 -0.328 166.8 %
Earnings after taxes 0.152 -0.411 137.0 %
Earnings per share 0.03 EUR -0.08 EUR 137.5 %
Equity as of 31 March (2011: 31 Dec) 12.465 12.254 1.7 %
Balance sheet total as of 31 March 20.396 20.491 -0.5 %
(2011: 31 Dec)
Free liquidity as of 31 March (2011: 1.073 1.883 -43.0 %
31 Dec)
Employees Group as of 31 March (2011: 230 239 -3.8 %
31 Dec)
Alphaform AG, based in Feldkirchen near Munich and founded in 1996, is a
production company for complex components and products produced in smaller
batches. Alphaform is among the European market leaders in prototyping, the
production of near-series prototypes, particularly for the automotive and
capital goods industries. The company has a leading position throughout
Europe in the manufacturing of orthopaedic implants and instruments.
Alphaform's shares are listed in the Prime Standard segment of the
Frankfurt stock exchange (code: ATF).
The core competence of Alphaform lies in its extensive application
expertise for processes and materials for the additive production of
complex prototypes, tools, individual components and small series of
plastics and metals. The company's work focuses on the orthopaedic and
medical technology, automotive, aviation and aerospace industries. There
are Alphaform subsidiaries in Germany, Finland, Sweden and the UK.
Contact:
Dr. Thomas Vetter
CEO
ALPHAFORM AG
Kapellenstraße 10
85622 Feldkirchen
Tel.: +49 89 905002 21
Fax: +49 89 9050021021e-mail: tvetter(at)alphaform.de
Internet: www.alphaform.de
End of Media Release
---------------------------------------------------------------------
09.05.2012 Dissemination of a Press Release, transmitted by DGAP - a
company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: Alphaform AG
Kapellenstraße 10
85622 Feldkirchen
Germany
Phone: +49 (0)89 905002 - 0
Fax: +49 (0)89 905002 - 90
E-mail: ir(at)alphaform.deInternet: www.alphaform.de
ISIN: DE0005487953
WKN: 548795
Listed: Regulierter Markt in Frankfurt (Prime Standard);
Freiverkehr in Berlin, Düsseldorf, Hamburg, München,
Stuttgart
End of News DGAP-Media
---------------------------------------------------------------------
168869 09.05.2012
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
" alt="Bayfield Drills 13.5m of 5.13 g/t Au and 25.21 g/t Ag in Developing East Discovery Zone at Burns Block in Rainy River District, NW Ontario">
" alt="Majestic Gold: Disclosure Clarification">
Datum: 09.05.2012 - 06:06 Uhr
Sprache: Deutsch
News-ID 1112236
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
Phone:
Kategorie:
Business News
Anmerkungen:
Diese Pressemitteilung wurde bisher 66 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"First quarter of 2012: Alphaform with clearly positive result
"
steht unter der journalistisch-redaktionellen Verantwortung von
Alphaform AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
